Single or multiple nutritional hormone receptor modulators for chronic kidney disease

Clicks: 9
ID: 327870
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #101 of 153 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The global rise in obesity and type 2 diabetes mellitus (T2DM) has contributed substantially to the increasing burden of chronic kidney disease (CKD), cardiovascular disease, and heart failure, highlighting the need for therapeutic strategies capable of addressing multiple components of the cardio-renal-metabolic axis. Incretin-based therapies have undergone an evolution from glucose-lowering agents to treatments with broad metabolic, cardiovascular, and renal effects. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated clinically meaningful reductions in cardiovascular events and have emerged as important therapies for kidney protection. Evidence from cardiovascular and kidney outcome trials, culminating in the FLOW study, has established semaglutide as a clinically relevant strategy for reducing kidney and cardiovascular risk in patients with T2DM and CKD. Beyond single-receptor agonism, the development of dual and triple incretin receptor agonists has expanded the therapeutic possibilities. Tirzepatide, a dual GLP-1/GIP receptor agonist, has demonstrated favourable kidney outcomes compared with dulaglutide, while early studies of the dual GLP-1/glucagon receptor agonist cotadutide suggest additional benefits on albuminuria and cardiorenal risk markers. Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, has shown promising effects on kidney-related parameters, although the mechanisms underlying observed increases in estimated glomerular filtration rate remain uncertain. Accumulating evidence suggests that incretin-based therapies may exert renoprotective effects through pathways extending beyond glycemic control and weight reduction, including improvements in endothelial function, microvascular integrity, inflammation, fibrosis, and renal hemodynamics. Nevertheless, important questions remain regarding the mechanisms of kidney protection, the interpretation of kidney function changes in the setting of substantial weight loss, and the long-term renal benefits of multi-receptor modulators. Ongoing mechanistic studies and dedicated outcome trials will further define the role of incretin biology in the prevention and treatment of CKD.
Reference Key
openalex_W7211866356 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hiddo J.L. Heerspink
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag311
URL
https://doi.org/10.1093/ckj/sfag311
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.